Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
J Cardiol. 2019 Feb;73(2):151-155. doi: 10.1016/j.jjcc.2018.07.008. Epub 2018 Oct 23.
A drug-coated balloon (DCB) has been designed as a new device for the treatment of coronary artery disease. The data regarding DCB-treated lesions in large coronary artery are limited. The purpose of our study was to explore the effectiveness and safety of DCB in large coronary artery.
We prospectively analyzed all patients treated with DCB in de novo lesions consistent with inclusion criteria between May 2015 and April 2017. The observed outcomes included target lesion revascularization (TLR), myocardial infarction, cardiac death and non-cardiac death, and major adverse cardiac events (MACE).
There were 92 patients including 94 coronary de novo lesions treated in all. The most often utilized DCB diameters were 3.0 mm (41.5%) and 3.5 mm (39.4%). Two acute closures occurred in hospital. Six bailout drug-eluting stents were used in the percutaneous coronary interventions (6.4%). Quantitative coronary angiography measurement at follow-up showed late lumen loss was -0.02 ± 0.49 mm. The TLR rate and overall MACE rates were 4.3% and 4.3% during the follow-up period in the whole patient population, respectively.
Our study showed that the "DCB only" strategy is safe and efficient in large vessel lesions of patients whose predilation achieved an acceptable result.
药物涂层球囊（DCB）已被设计为一种治疗冠状动脉疾病的新型装置。关于在大冠状动脉中使用 DCB 治疗病变的数据有限。我们的研究目的是探讨 DCB 在大冠状动脉中的有效性和安全性。
我们前瞻性分析了 2015 年 5 月至 2017 年 4 月期间符合纳入标准的所有使用 DCB 治疗的初发病变患者。观察的结果包括靶病变血运重建（TLR）、心肌梗死、心脏性死亡和非心脏性死亡以及主要不良心脏事件（MACE）。
共有 92 例患者（94 处冠状动脉初发病变）接受了治疗。最常使用的 DCB 直径为 3.0mm（41.5%）和 3.5mm（39.4%）。有 2 例在住院期间发生急性闭塞。有 6 例患者在经皮冠状动脉介入治疗（PCI）中使用了挽救性药物洗脱支架（6.4%）。随访时的定量冠状动脉造影测量显示晚期管腔丢失为-0.02±0.49mm。在整个患者人群中，随访期间 TLR 发生率和总体 MACE 发生率分别为 4.3%和 4.3%。
我们的研究表明，在预扩张获得可接受结果的患者中，对于大血管病变，“仅 DCB”策略是安全有效的。
